Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2023-03440 | Other Identifier | NCI-CTRP Clinical Trials Registry |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To collect information about how patients in the pain management clinic use cannabis/CBD, including how often it is used, why it is used (for example, to manage pain or other symptoms), and where patients get their information on cannabis/CBD for pain management
Objectives
Primary Objective:
The primary objective of this study is to investigate the prevalence of current and prior cannabis and/or CBD use in cancer patients who present to the pain management clinic at MDACC.
Secondary Objectives:
The secondary objective is to investigate the reason for cannabis/CBD use (e.g. pain, neuropsychiatric symptoms, recreational or other use), degree of symptom improvement with use, frequency of use, methods of use (e.g. inhaled vs. ingested), sources of information on cannabis/CBD, and patient interest in learning more from their physicians about cannabis/CBD for cancer pain.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cannabis (Marijuana) and Cannabidiol (CBD) | This is a survey to determine the number of cancer pain patients who use and/or used Marijuana and/or CBD for pain or other symptom burdens. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cannabis (Marijuana) | Behavioral | The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education. |
| Measure | Description | Time Frame |
|---|---|---|
| Cannabis (Marijuana) and CBD (Cannabidiol for Cancer Pain Survey | Score scale ranges from 1-5, Extremely interested(1),Not Interested (5) | through study completion; an average of 1 year. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
M D Anderson Cancer Center
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Salahadin Abdi, MD,PHD | M.D. Anderson Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | United States |
Not provided
| Label | URL |
|---|---|
| M D Anderson Cancer Center | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C587251 | nabiximols |
| D002185 | Cannabidiol |
| ID | Term |
|---|---|
| D002186 | Cannabinoids |
| D013729 | Terpenes |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
| Cannabidiol (CBD) | Behavioral | The level of interest in learning more about cannabis for cancer pain, we can better facilitate a patient-centered approach to comprehensive treatment plans through patient education |
|